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Abstract
In rheumatoid arthritis, T cells and B cells participate in the immune responses evolving in
the synovial lesions. Interaction between T cells and B cells is probably antigen specific
because complex microstructures typical of secondary lymphoid organs are generated.
Differences between patients in forming follicles with germinal centers, T-cell–B-cell
aggregates without germinal center reactions, or loosely organized T-cell–B-cell infiltrates
might reflect the presence of different antigens or a heterogeneity in host response patterns
to immune injury. Tertiary lymphoid microstructures in the rheumatoid lesions can enhance
the sensitivity of antigen recognition, optimize the collaboration of immunoregulatory and
effector cells, and support the interaction between the tissue site and the aberrant immune
response. The molecular basis of lymphoid organogenesis studied in gene-targeted mice will
provide clues to why the synovium is a preferred site for tertiary lymphoid tissue. B cells have
a critical role in lymphoid organogenesis. Their contribution to synovial inflammation extends
beyond antibody secretion and includes the activation and regulation of effector T cells.
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Introduction
Protective immune responses directed against infections
and malignancies are generated in specialized lymphoid
organs localized at strategic sites [1,2]. Their main
purpose is to optimize immune reactions by bringing
together rare antigen-specific T cells and B cells and by
providing the infrastructure for the optimal pairing of lym-
phocytes and accessory cells [3]. The degeneration of
such secondary lymphoid organs causes severe immuno-
deficiency, fortifying the concept that spatial arrange-
ments, in addition to frequencies of immune cells, are criti-
cal for immunoresponsiveness. Although lymph nodes,
spleen, tonsils, and Peyer’s patches are the main sites of
host immune reactions, lymphoid microstructures can also
emerge, aberrantly creating novel sites for the activation
and maturation of T cells and B cells. Aberrant lymphoid
organogenesis is generally associated with pathologic
immune responses [4]. A prime example is rheumatoidArthritis Research    Vol 2 No 6 Weyand et al
arthritis (RA), in which complex lymphoid microstructures
are created in the inflamed synovial membrane [5,6].
Specifically, synovial lesions form highly sophisticated
spatial arrangements of T cells and B cells, at times pro-
ceeding to the generation of germinal centers (GCs).
Extranodal GCs can occur in other autoimmune diseases,
but they are encountered infrequently. Tertiary lymphoid
organizations have been described in some patients with
Sjögren’s syndrome and occasionally in the pancreas of
mice with type I diabetes mellitus [7,8].
The presence of GCs in the rheumatoid joint emphasizes
that these inflammatory lesions are involved in generating
strong immune responses [1,9], almost certainly to spe-
cific antigens. In addition, it lends support to the critical
role of both T cells and B cells in rheumatoid pathogene-
sis. The impetus for understanding how these extranodal
lymphoid organs arise is obvious: they might provide clues
to the antigens driving the immune process. New thera-
peutic targets might be identified when the cellular and
non-cellular components of synovial GC reactions have
been identified, and fundamental insights into the process
of lymphoid neogenesis might be gained. In addition,
because only a subset of RA patients is able to generate
GCs, a molecular understanding of this pathway might
lead to the identification of markers useful in dissecting
the heterogeneity of the RA syndromes.
B-cell follicles in rheumatoid synovitis
Synovial infiltrates in rheumatoid synovitis produce an array
of lesions [10]. Regular participants in the tissue infiltrates
are T cells, macrophages, and hyperplastic synoviocytes
[5,11]. In many, but not all, patients, B cells also accumu-
late in the synovial membrane. In a series of 173 RA
patients, 60% of synovial biopsies were classified as
having diffuse infiltrates with T cells and B cells and no dis-
tinct topography. In 34% of patients, tissue-invading T cells
and B cells were compartmentalized. As in secondary lym-
phoid organs, B cells cluster in follicle-like structures in a
close spatial relationship to CD4+ T cells and CD8+ T
cells. The ratio of T cells to B cells accumulating in the folli-
cles is strictly regulated, indicating a well-choreographed
chain of events in the formation of this anatomy [6].
Synovial T-cell–B-cell follicles occur in two mutually exclu-
sive and equally frequent forms (Figure 1). The first are
T-cell–B-cell aggregates that lack proliferating B cells in
the center, are composed mostly of IgD+ B cells, do not
have follicular dendritic cell (FDC) networks, and therefore
have not generated GC reactions; the second are
T-cell–B-cell aggregates that have all the morphologic
characteristics of classical GCs, including well-developed
FDC networks and Ki-67+ proliferating B-cell blasts that
have downregulated IgD. These FDC+ T-cell–B-cell
aggregates have all the components for GC reactions,
and molecular studies have documented that immunoglob-
ulin gene hypermutations are generated [12–14]. In
essence, the rheumatoid synovium can serve as a site for
aberrant lymphoid organogenesis. However, some obser-
vations have identified special features of synovial GCs in
comparison with their classical counterparts in secondary
lymphoid organs (Table 1). A recent study has used micro-
manipulation to isolate CD20+ B cells and tissue-residing
plasma cells [14]. B cells were activated, underwent
clonal expansion, and shared identical rearrangements.
Surprisingly, these rearrangements, supposedly directed
at generating high-affinity antibodies against the initiating
antigen, were not detected in the plasma cells. It is possi-
ble that events in synovial GCs do not totally mimic similar
pathways in lymph nodes.
The question is also raised as to the origin of synovial
plasma cells, which have a critical role in secreting disease-
Figure 1
The formation of lymphoid microstructures by T cells and B cells in
rheumatoid synovitis. T cells and B cells infiltrating the synovial
membrane are arranged into highly organized structures. Synovial
lymphoid microstructures include two mutually exclusive types of T-
cell–B-cell clusters, those lacking GCs (a, c) and follicles with central
GCs (b, d). In both microstructures, T cells and B cells are mixed in a
well-maintained ratio. Centroblasts and centrocytes in the follicular
sample indicate a GC reaction that is missing from the aggregate
sample. The stain in (a) and (b) was hematoxylin. CD23-expressing
FDC networks were detected by immunoperoxidase technique with
3¢,3¢-diaminobenzidine tetrahydrochloride substrate (c, d). Centers of
follicles with GCs were occupied by FDC networks, reminiscent of
typical secondary follicles in lymph nodes. No FDCs were identified in
T-cell–B-cell aggregates that lacked GCs. It is not known whether
synovial T-cell–B-cell aggregates resemble structures represented in
secondary lymphoid tissues.
(a)                                                       (b)
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relevant antibodies. Are they simply outliving rapidly cycling
CD20+ B cells? Are they recruited to the lesions instead of
being generated in situ? What are the mechanisms attract-
ing, retaining, and guiding B cells and plasma cells in the
synovial tissue? Another typical feature of synovial GCs is
the presence of CD8+ T cells expressing CD40 ligand
(CD40L) [6]. CD8 T cells have not yet been implicated in
the series of events leading to GC reactions [15]. When
synovial tissues with lymphoid follicles were analyzed, fre-
quencies of tissue-residing CD8 T cells were identified as
a distinguishing factor. CD8+CD40L+ T cells were absent
from tissues with T-cell–B-cell aggregates and no GC for-
mation, but they were enriched in synovial samples with
typical GCs. With the use of microscopic imaging, these
cells were localized at the outskirts of the T-cell–B-cell
clusters. Preliminary functional data from these CD8 T cells
are available. They were described as lacking the pore-
forming enzyme perforin, a molecular marker associated
with cytolytic capability, and instead transcribed high con-
centrations of interferon-g (IFN-g) [6]. Why would CD8
T cells, instead of CD4 T cells, have a role in regulating
synovial GCs? One possible interpretation could be that
the antigens recognized in these lymphoid microstructures
preferentially target CD8 T cells responsive to endoge-
nously processed antigens.
The choreography of lymphoid organogenesis
The complexity of the topographic arrangement and func-
tion of GCs is the result of an orchestrated effort by
lymphocytes, non-lymphoid stromal cells, cytokines,
chemokines, and growth factors controlling the traffic of
leukocytes into compartments of lymphoid organs [16,17],
optimizing contact to antigens and providing the infra-
structure for optimal cooperation to yield effective immune
responses (Figure 2). GCs are critical for the affinity matu-
ration of antibodies and the generation of B-cell memory.
As they progress through the GC, B cells selectively
mutate their immunoglobulin genes and are selected on
antigen presented on FDCs, ultimately resulting in the pro-
duction of high-affinity neutralizing antibodies specific for
viral antigens and bacterial exotoxins. By receiving appro-
priate signals from T cells participating in the GC reaction,
mutated B cells expressing high-affinity antibodies differ-
entiate to become antibody-forming plasma cells or
memory B cells; B cells with low affinity are eliminated.
GCs also have a role in removing B cells that form self-
reactive antibody by forcing them to undergo apoptosis. In
general, GCs cannot be formed unless supported by
antigen-specific CD4 T cells. Although a recent report
indicates that under unusual circumstances, high-affinity B
cells can be induced to generate GCs in response to
(4-hydroxy-3-nitrophenyl)acetyl Ficoll in the absence of
Table 1
Features of secondary lymphoid tissues in lymph nodes and tertiary lymphoid tissues in rheumatoid synovium
Lymph node  Lymph node  Synovial CD23-null  Synovial CD23+
Tissue primary follicles secondary follicles T-cell–B-cell aggregates follicles
Organized T-cell zones + + + +
Follicular clustering of B cells + + + +
Proliferating B cells – + – +
Hypermutated immunoglobulin genes – + ? +
Plasma cells with identical rearrangements – + ? –
CD23+ FDC networks + – – +
CD8+CD40L+ cells – – – +
Figure 2
Schematic model of specialized cell populations and chemokines
instrumental in the formation of GCs in secondary and tertiary
lymphoid tissues. BCB, centroblastic B cell; BCC, centroclastic B cell;
BM, memory B cell; BP, plasma B cell; DC, dendritic cell; HEV, high
endothelial venule; TN, naive T cell; TP, primed T cell.T cells. GCs formed without T-cell help were possible only
when B-cell receptors were extensively crosslinked and
when high frequencies of antigen-specific B cells were
available [18]. These GCs also had a short lifespan and
aborted conspicuously at the time when B cells are nor-
mally selected by antigen-reactive T cells. Two receptor–
ligand pairs are crucial in mediating the T-cell–B-cell
contact that is essential for successful GC reactions. GC
T cells and B cells communicate through the interaction of
CD28 and CD80/CD86 and through the crosslinking of
CD40 on the surface of B cells by CD40L expressed on
activated T cells [19–22].
Significant progress in understanding the events leading
to the recruitment, retention, compartmentalization, activa-
tion, and recirculation of lymphocytes in and out of sec-
ondary lymphoid tissues has been made in recent years.
Mice with spontaneous abnormalities in lymphoid organo-
genesis or with targeted homologous deletions of specific
mediators have been instrumental in developing a model
of how immune cells are brought together in defined
spaces to generate immune responses. After being
released from primary lymphoid organs, such as bone
marrow or the thymus, lymphocytes migrate into lymph
nodes by crossing the endothelium in a multistep process.
Supported by selectins, lymphocytes start to roll on the
endothelial layer and then adhere firmly via integrins [23].
It is currently believed that the mass transit of resting lym-
phocytes across specialized high endothelial venules is
facilitated by the expression of secondary lymphoid tissue
chemokine (SLC) on the endothelial cells [24–26]. Mice
homozygous for a spontaneous mutation plt (paucity of
lymph node T cells) lack SLC expression and have defec-
tive trafficking of T cells into lymph nodes [27–29]. In
addition, T cells lacking the SLC receptor, C-C chemokine
receptor-7 (CCR7), are markedly impaired in their ability to
enter lymph nodes and Peyer’s patches [30]. B-cell traf-
ficking in plt mice and in CCR7-deficient mice is affected
much less, which is compatible with a dichotomy in regu-
lating T-cell and B-cell migration. Once lymphocytes have
accessed lymphoid tissues, they effectively search out
certain subcompartments; B cells accumulate in B-cell fol-
licles and T cells home to areas rich in T cells. This
process is at least partly under the control of chemokines.
The current model is that the movement of T cells is
guided by two ligands that both bind to CCR7: SLC and
Epstein–Barr virus-induced molecule 1 ligand chemokine
(ELC) [29,31–34]. These ligands can probably be pro-
duced by dendritic cells, macrophages, and other non-
hematopoietic cells residing in the T-cell zones [35–37].
Mice with the plt mutation, which have a defect in express-
ing SLC and ELC, have impairment not only in T-cell entry
into lymph nodes but also in organizing T cells in the T-cell
areas. In addition, trafficking of T cells through secondary
lymphoid tissues is severely disturbed in CCR7-deficient
mice [27]. Two molecular pathways have been implicated
in regulating SLC and ELC production: signaling by lym-
photoxin-ab (LTab) seems to be necessary for the induc-
tion of SLC and ELC [1,38,39], and mice deficient in
Re1 B, a member of the nuclear transcription factor NF-kB
family, have an impairment in secreting SLC [40].
T-cell–B-cell follicles would not be preferred sites of
immune recognition unless chances for antigen encounter
were markedly enhanced [41]. This is achieved by trans-
porting antigen by specialized cells to the T-cell and B-cell
zones of secondary lymphoid organs. Dendritic cells
(DCs) are positioned in peripheral tissue; there they
capture antigen, transform into activated DCs, become
migratory, access lymphatic vessels, and travel to the
draining lymph nodes, where they migrate deep into the
T-cell areas [42,43]. Recruitment of DCs to the lymph
nodes, and the concomitant ferrying of antigens to sites of
critical mass, involves the upregulation of CCR7, render-
ing these specialized cells responsive to SLC and ELC
[44–46]. It is now believed that SLC and ELC facilitate
the entry of DCs into lymphatics and their trafficking to the
T-cell zones [26]. DCs in T-cell zones are highly effective
antigen-presenting cells (APCs), permitting the priming of
naive T cells. Interestingly, such DCs have been identified
as the cellular source of ELC and also of the chemoattrac-
tant dendritic cell-derived C-C chemokine-1 (DC-CK 1),
raising the possibility that they attract naive T cells to
enhance the opportunity for APC-T cell interaction
[47,48]. Once T cells have been primed, they become
responsive to other chemokines, guiding their movements
in the search for their B-cell partners [49]. B cells that
have bound sufficient antigen are redirected from the
migration route of naive B cells and move to the boundary
of the B-cell and T-cell zones [50].
A critical role in the compartmental homing of B cells has
been assigned to the ligand binding C-X-C chemokine
receptor-5 (CXCR5). CXCR5-deficient B cells lack the
ability to migrate to splenic follicles, and targeted disrup-
tion of CXCR5 prevents the development of B-cell follicles
in the spleen [51,52]. The ligand for this receptor has
been named B-lymphocyte chemoattractant (BLC). This
CXC chemokine is probably constitutively expressed by
stromal cells in the center of follicles, presumably by FDCs
[53]. Thus, B-cell recruitment seems to be controlled by
follicular structures. This model does not provide an expla-
nation for the initial establishment of follicles unless the
assumption is made that FDCs are present before B cells
are recruited. If that were so, follicle formation would ulti-
mately depend on whether FDCs can be developed or
selectively attracted to tissue sites.
Some experimental evidence suggests that antigen-
specific T cells, when activated by DCs, upregulate the
expression of CXCR5, rendering them responsive to BLC
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producing FDCs, meet B cells specific for the same
antigen, and support the generation of a GC. This model
would re-emphasize the critical position of FDCs in the
choreography of lymphoid organogenesis [54]. The devel-
opment and the function of FDCs has been linked with the
presence of the cytokines LTab and tumour necrosis
factor-a (TNF-a) [55–57]. One of the activities mediated
by these cytokines seems to be the induction of BLC.
Given the critical participation of BLC-producing FDCs,
LTab and TNF-a could also be instrumental in regulating
aberrant lymphoid neogenesis.
Aberrant lymphoid organogenesis in
rheumatoid synovitis
Synovial membrane is ordinarily not a site for lymphoid
structures to emerge. In many RA patients, inflammation
can persist for years and infiltrating lymphocytes do not
acquire defined topographical arrangements. The subset of
RA patients with classical GC reactions usually generate
numerous follicles, possess this pattern of inflammation in
essentially all affected joints, and maintain it over time
without switching to other microstructures. Most patients
with follicular synovitis form rheumatoid nodules outside
the joint. These structures closely resemble granulomatous
reactions but, remarkably, in the synovial membrane, follicu-
lar arrangements are not mixed with granulomas [10].
It has been proposed that priming of the tissue site has to
be achieved during a window of embryonic development
to permit the subsequent appearance of primary follicles
[1]. The mechanisms of priming are not understood, but it
is difficult to envisage that such a priming event would
condition the synovium in some patients while sparing
others. Nurse-like cells that are able to activate B cells and
provide survival signals have been described in rheuma-
toid synovitis, but it is currently unclear whether their pres-
ence correlates with extranodal GCs [58]. Patterns of
cytokine production in the synovial microenvironment are
clearly distinct in patients with diffuse, follicular, or granu-
lomatous synovitis [10]. Tissue levels of TNF-a, interleukin
(IL)-1b, and IFN-g are low in samples with diffuse synovitis.
Follicular synovitis is characterized by an increased tran-
scription of IFN-g and is typically associated with high con-
centrations of IL-10. Formation of granulomas is correlated
with the production of the highest tissue concentrations of
IFN-g and IFN-g transcripts and, interestingly, lacks the
production of IL-10 in situ. Synovial IL-4 mRNA was found
in some patients, indicating that patterns similar to those
for both T helper 1 (TH1) and T helper 2 (TH2) cells might
be present in rheumatoid synovitis [59]. T cells with the
TH1 and TH2 phenotypes have been described to express
distinct profiles of chemokine receptors [60–62].
Given the central role of chemokines in the establishment
of lymphoid microstructures, it needs to be examined
whether the differences in the inflammatory cytokines are a
reflection of the selective recruitment of distinct popula-
tions of T cells into the synovial membrane. Another possi-
bility is that chemokine receptor expression on activated T
cells is influenced by the site of initial priming. Support for
this model has come from the observation that CCR4+ T
cells accumulate preferentially at sites of cutaneous inflam-
mation but avoid the intestinal tract [63]. Finally, it could be
proposed that the site of priming and also the nature of the
antigen have a direct impact on modulating the chemokine
receptor patterning of T cells, thus dictating their trafficking
to and retention in inflammatory lesions.
Little is known about the molecular components of the
synovial microenvironment that determine lymphoid neo-
organogenesis. Cell migration in tissue sites is ultimately
regulated by chemokine gradients that are established by
local deposits but also by the binding of these
chemokines, highly basic proteins, to sulfated matrix com-
ponents and proteoglycans. The final decision about the
specific arrangement of lymphocytes in the inflamed syn-
ovial membrane might also depend on the composition of
extracellular matrix proteins and their distribution in the
soft tissue layer.
An important aspect of T-cell–B-cell physiology in rheuma-
toid synovitis is related to the precise function that these
immune cells have in the disease process. The focus of
GCs in generating high-affinity antibodies suggests that
the major function of synovial B cells is the secretion of
immunoglobulins, probably including rheumatoid factor
[64,65]. Recent data suggest that B cells might contribute
to disease mechanisms through pathways not directly
dependent on the release of disease-relevant antibodies.
In murine models of autoimmune disease, including
MRL/lpr mice and non-obese diabetic mice, B cells have
been found to be instrumental in the disease process
[66,67]. The accumulation of activated T cells, of both the
CD4+ and the CD8+ subsets, in MRL/lpr mice is highly B-
cell dependent [68,69]. The underlying mechanism does
not involve antibody-mediated activation because
mIgM.MRL/lpr mice, which have B cells but are deficient
in serum Ig, continue to generate manifestations of lupus
[67]. B cells in the rheumatoid synovium seem to have
similar functions. Depletion of B cells from a rheumatoid
synovium–severe combined immunodeficiency (SCID)
mouse chimera not only destroyed the lymphoid follicles
but also abrogated IFN-g production by T cells and
IL-1/TNF-a production. In these experiments, rheumatoid
synovium was grafted into SCID mice, the animals were
treated with anti-CD20 monoclonal antibody (Rituxan),
and transcription of cytokines in situ was quantified from
the retrieved grafts [70].
It is possible that B cells could facilitate T-cell activation
and inflammatory tissue damage by secreting cytokines
http://arthritis-research.com/content/2/6/457and chemokines. A more likely model is that B cells func-
tion as critical APCs, taking up antigens through their
immunoglobulin receptor and presenting it to CD4 T cells
[71,72]. Antigens driving rheumatoid synovitis might be
particularly susceptible to capture by B cells in the syn-
ovial membrane, favoring B cells as APCs for recruited
T cells. The implications of such a mechanism are obvious
because the immune response could be disrupted by
eliminating B cells from the inflammatory lesions.
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